ESC 365 - BRaf inhibitors, dabrafenib and SB590885, enhance ERK1/2 signalling in cardiomyocytes and increase angiotensin II-induced cardiac hypertrophy.

HFA Premium Access

BRaf inhibitors, dabrafenib and SB590885, enhance ERK1/2 signalling in cardiomyocytes and increase angiotensin II-induced cardiac hypertrophy.

Session: Poster Session 1 - Basic Science - Therapeutic approach

Topic: Cell Signalling

Speaker: Professor A. Clerk (Reading, GB)

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Congress Presentation

Add to my library

About the speaker

Professor Angela Clerk

University of Reading, Reading (United Kingdom of Great Britain & Northern Ireland)

0 follower

9 more presentations in this session

Cardiac gene therapy with phosphodiesterases PDE2A and PDE4B in a mouse model of heart failure

Speaker: Mr J. Margaria (Turin, IT)

Acute and subacute functional effects of relaxin-2 on human mammary artery

Speaker: Doctor F. Vasques-Novoa (Porto, PT)

Microencapsulated insulin-like growth factor 1 improves cardiac function after experimental myocardial infarction in comparison to low-dose mesenchymal stem cells

Speaker: Doctor C. Baez Diaz (Madrid Caceres, ES)

Pharmacological activation of sphingosine 1-phosphate receptor 1 (S1pr1) enhances arteriole formation and improves cardiac function after myocardial infarction (MI)

Speaker: Professor L. Zhang (Shanghai, CN)

Raf kinase inhibitor protein regulates fibrosis depending on myocardial oxidative stress

Speaker: Doctor A. Kazakov (Homburg, DE)

Access the full session

Poster Session 1 - Basic Science - Therapeutic approach

Speakers: Professor A. Clerk, Mr J. Margaria, Doctor F. Vasques-Novoa, Doctor C. Baez Diaz, Professor L. Zhang...

About the event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources